secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125933
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026
--------------------------------------------------------------------------------

- Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.
- Cash $14.6M at Sep 30; pro forma after Oct offering ~$23.7M, funds ops into H1 2026.
- Completed Nov 1 public offering: 2.72M shares at $3.75, gross proceeds $10.2M.
- Phase 2b CARPO: win ratio 1.64 (p=0.0372) for high-dose Auxora vs placebo; 100% relative risk reduction in new-onset severe respiratory failure.
- Expects Phase 3 start in 2025; topline data from KOURAGE (AKI) and CRSPA (AIPT) trials in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/0000950170-24-125933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer